Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease.

Cell reports. Medicine

GLP-1 and MASH: When weight loss isn't the whole story.

Cell metabolism

Brain Neuromodulation via Endoscopic Gastric Implant Improves Glycemic Control in Insulin-Dependent Type-2 Diabetes: First-in-Human Feasibility and Autonomic Response Study.

Journal of laparoendoscopic & advanced surgical techniques. Part A

Semaglutide Modulates Visceral Adipose Tissue Lipid Metabolism in Type 2 Diabetic Mice: A Lipidomics Study.

Frontiers in bioscience (Landmark edition)

A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice.

Diabetes, obesity & metabolism

Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers.

Diabetes, obesity & metabolism

Comment on 'The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon-Like Peptide-1-Based Therapies'.

Diabetes, obesity & metabolism

Copper peptide activated cascade catalysis for glucose regulation and hypoxia reversing in infected diabetic wound healing.

Materials today. Bio

Hims & Hers is going all-in on #peptides. Is $HIMS evolving from a GLP-1 to a peptide company? Let's discuss in the comments 👇 ❤️ Like 🟦 Save 🔁 Repost $HIMS is actively building operational capacity for peptide active pharmaceutical ingredient (API) production. The company https://t.co/YU99GqkJR5

BREAKING $HIMS Another Upgrade| $40| BUY rating🚀 This only proves @MikeLongTerm was right again and again and again! These PTs are still very behind with FY2026 Revenue and earning growth or FY2027. Analysts will soon be revised nonstop to 3 digits IMO. Not Financial Advice! https://t.co/P53V80HOpX https://t.co/6xXvbCMgBK

Three things reshaping the peptide industry right now: • Medicare now covers GLP-1s for weight loss $50/mo, first time ever (launched July 1) • FDA panel decides July 23 on BPC-157, TB-500, Semax + 4 more • Novartis bet up to $1.7B on peptide drugs Federal access.

Top compounds on PeptideBase by provider coverage: 1. Semaglutide — 676 2. Tirzepatide — 444 3. BPC-157 — 402 4. NAD+ — 349 5. Sermorelin — 333 6. Ipamorelin — 320 7. CJC-1295 — 306 Coverage = where the market concentrated, not where the evidence is. Disclaimer: Research use

@IhabFathiSulima The most likely reason is: > History of Medullary Thyroid Carcinoma (MTC) or MEN2 syndrome. ⚠️ Why? Ozempic (semaglutide), a GLP-1 receptor agonist, carries a boxed warning and is contraindicated in patients with: 🦋 Personal or family history of Medullary Thyroid Carcinoma

RT @MounjaroNotes: Tirzepatide is GLP-1 + GIP, but semaglutide is more GLP-1-heavy. Since GLP-1 plays a major role in satiety and hunger s…

GLP/peptide talk translation: • “Gray market = sold outside authorized prescription/pharmacy channels. • “Research” = labeled “for research—not approved for human use” to enable sale in the US. • GLP-1 = the hormone pathway targeted by this drug class (Sema) • GLP-2 = https://t.co/jw0vVEq3xI

July update 🧪 Our marketplace selection just got bigger and fully back in stock. We expanded product across our sources, with 🇦🇺 Australia & 🇨🇦 Canada now getting the same low domestic rates as the US, EU & UK. Newly available: 🇨🇦 AOD-9604 · BPC-157 · CJC-1295 (no DAC) · https://t.co/i0XMWr34aK